Indiana University
MAPS & DIRECTIONS Maps FIND PEOPLE Find People

Clinical Trials

Studies Currently Enrolling:

 Investigator  Initiated: Travers 

Pilot Study of Role of Chronic Immunosuppression in UVB irradiation effects:  
Examining whether  subjects who have undergone  solid organ transplantation with concomitant immunosuppression therapy exhibit  decreased production of the insulin-like  growth factor 1(IGF-1)
 and thus have abnormal  skin responses to ultraviolet B (UVB) radiation. 

Adults, aged 25-50, who have undergone solid organ (eg, kidney, lung, heart, liver) transplant  at least 5 years ago & aged-matched controls. Since insulin can act as an agonist on the IGF-1receptor, we are excluding

subjects who have diabetes mellitus. We are also excluding subjects who have known photosensitivity or are on any photo-sensitizing medications, or have abnormal  scarring or a history of problems with skin infections.

 Recruitment  Status:  1 Subject completed

 Need 11 Transplant Patients & 12 Healthy  (who will be matched to completed transplant subjects)

 

 Investigator  Initiated:  Somani

 Effect of Dermal  Rejuvenation on the UVB Response of Geriatric  Skin:
Examining the ability of dermal rejuvenation therapies to protect  geriatric  skin from ultraviolet light (UVB)-induced carcinogenesis. Adults, aged  65 years, skin type must be "Fair", Fitzpatrick type I or II.   Excluded: Subjects who have underlying diseases that could affect wound healing (eg, diabetes mellitus), on medications that are known photosensitizers, or have a history of abnormal scarring (eg, keloids) will be excluded.


Recruitment  Status: 8 Subjects completed;  2 Active

Need 14 more subjects aged > 65 years

 


 TKL Research-SCREENING NOW

Adult Psoriasis: Phase 2a for Efficacy, Safety, Tolerability, and Pharmacokinetics; IV Infusion drug (Competitive Enrollment) treatment: 20 weeks 

Male or female patients, ages ≥ 18 and ≤ 70 years, weight  range: ≥ 50 kg and ≤ 140 kg, with chronic plaque psoriasis > 1 year, Body Surface Area (BSA) 10%, disease severity (Psoriasis Area Severity Index) PASI ≥ 10%, must have at least 1 1esion for target lesion assessments. No biologic agents for 3 months prior to enrolling into the studv (or 5 drug half-lives, which ever longer), no systemic anti-psoriatic medications for 4 weeks and no Ultra-violet light type 8 (UVB) irradiation or topical drugs (except emollients} for 2 weeks before treatment .

 

PLEASE REFER POTENTIAL SUBJECTS TO MIMI  @ 274-8750

mlengeri@iu.edu